Akebia Therapeutics®, Inc. announced the appointment of Erik Ostrowski as Chief Financial Officer. Mr. Ostrowski is an experienced biotech executive with a diverse background spanning industry leadership roles, board service and investment banking. Mr. Ostrowski joins Akebia from Avrobio, where he served as President, Interim Chief Executive Officer and Chief Financial Officer, leading the execution of its merger with Tectonic Therapeutic.

Prior to Avrobio, Mr. Ostrowski was Chief Financial Officer of Summit Therapeutics where he led its initial public offering on Nasdaq. He was recently Chair of the Audit Committee of the Board of Directors of Faron Pharmaceuticals. Mr. Ostrowski also spent over ten years in investment banking including at Leerink Partners and Robertson Stephens.

Mr. Ostrowski earned his bachelor's degree in accounting and economics from Babson College and an MBA from the University of Chicago Booth School of Business.